66 related articles for article (PubMed ID: 31610237)
21. Efficacy of chidamide maintenance therapy versus autologous stem cell transplantation versus observation as a post-remission choice in the survival of adult patients with peripheral T-cell lymphoma: Post hoc analysis of a prospective, multicenter, phase 2 study in China.
Wang W; Zhang W; Su LP; Liu LH; Gao YH; Wang QS; Su H; Song YQ; Zhang HL; Shen J; Jing HM; Wang SY; Cen XN; Liu H; Liu AC; Li ZJ; Luo JM; He JX; Wang JW; O'Connor OA; Zhou DB
Ann Hematol; 2024 May; ():. PubMed ID: 38805037
[TBL] [Abstract][Full Text] [Related]
22. Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Garderet L; Gras L; Koster L; De Wreede L; Montserrat R; Vincent L; Fenk R; Karunanithi K; Deeren D; Kaufmann M; Kuball J; Ozdogu H; Cascon MJP; Passweg J; Rye A; Salmenniemi U; Snowden J; Hansen CT; Leleu X; Gastaud L; Sokolowska JD; Raj K; Beksac M; Schönland S; Hayden P; McLornan D
Haematologica; 2024 Mar; ():. PubMed ID: 38546696
[TBL] [Abstract][Full Text] [Related]
23. Simulation-Based Optimization of Sampling Schedules for Model-Informed Precision Dosing of Once-Daily and 4-Times-Daily Busulfan in Pediatric Patients.
Ben Hassine K; Daali Y; Gloor Y; Nava T; Théorêt Y; Krajinovic M; Bittencourt H; Satyanarayana Uppugunduri CR; Ansari M
Ther Drug Monit; 2024 Jun; ():. PubMed ID: 38885146
[TBL] [Abstract][Full Text] [Related]
24. Model-Informed Precision Dosing of Intravenous Busulfan in Thai Pediatrics Undergoing Hematopoietic Stem Cell Transplantation.
Puangpetch A; Thomas F; Anurathapan U; Pakakasama S; Hongeng S; Rachanakul J; Prommas S; Nuntharadthanaphong N; Chatelut É; Sukasem C; Le Louedec F
Ther Drug Monit; 2024 May; ():. PubMed ID: 38758634
[TBL] [Abstract][Full Text] [Related]
25. Sunitinib for the treatment of metastatic gastrointestinal stromal tumors: the effect of TDM-guided dose optimization on clinical outcomes.
Giraud EL; Westerdijk K; van der Kleij MBA; Guchelaar NAD; Meertens M; Bleckman RF; Rieborn A; Mohammadi M; Roets E; Mathijssen RHJ; Huitema ADR; Koolen SLW; Gelderblom H; Moes DJAR; Reyners AKL; Touw DJ; Keizer-Heldens P; Oosten AW; van der Graaf WTA; Steeghs N; van Erp NP; Desar IME;
ESMO Open; 2024 Jun; 9(6):103477. PubMed ID: 38833964
[TBL] [Abstract][Full Text] [Related]
26. Challenges and outcomes of a randomized study of early nutrition support during autologous stem-cell transplantation.
Kiss N; Seymour JF; Prince HM; Dutu G
Curr Oncol; 2014 Apr; 21(2):e334-9. PubMed ID: 24764716
[TBL] [Abstract][Full Text] [Related]
27. Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen.
Young PA; Gaut D; Kimaiyo DK; Grotts J; Romero T; Chute J; Schiller G; de Vos S; Eradat HA; Timmerman J
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):468-479. PubMed ID: 32229199
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of Autologous Stem Cell Transplant Consolidation in Primary Central Nervous System Lymphoma: A Mayo Clinic Experience.
Khurana A; Micallef IN; LaPlant BR; Patrick O'Neill B; Habermann TM; Ansell SM; Inwards DJ; Porrata LF; Paludo J; Bisneto JCV; Johnston PB
Biol Blood Marrow Transplant; 2020 Dec; 26(12):2217-2222. PubMed ID: 32818553
[TBL] [Abstract][Full Text] [Related]
29. BEAM versus pharmacokinetics-directed BuCyVP16 conditioning for patients with peripheral T-cell lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.
Stuver R; Mian A; Brown S; Devlin S; Caimi PF; Chinapen S; Dahi P; Dean R; Epstein-Peterson ZD; Hill B; Horwitz SM; Lahoud O; Lin R; Moskowitz AJ; Sauter C; Shah G; Winter A; Jagadeesh D; Scordo M
Am J Hematol; 2024 Jun; 99(6):1180-1183. PubMed ID: 38526002
[TBL] [Abstract][Full Text] [Related]
30. External Evaluation of Population Pharmacokinetic Models of Busulfan in Chinese Adult Hematopoietic Stem Cell Transplantation Recipients.
Huang H; Liu Q; Zhang X; Xie H; Liu M; Chaphekar N; Wu X
Front Pharmacol; 2022; 13():835037. PubMed ID: 35873594
[No Abstract] [Full Text] [Related]
31. Can First-Dose Therapeutic Drug Monitoring Predict the Steady State Area Under the Blood Concentration-Time Curve of Busulfan in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation?
Alsultan A; Albassam AA; Alturki A; Alsultan A; Essa M; Almuzzaini B; Alfadhel S
Front Pediatr; 2022; 10():834773. PubMed ID: 35463912
[TBL] [Abstract][Full Text] [Related]
32. Perspectives and Expertise in Establishing a Therapeutic Drug Monitoring Programme for Challenging Childhood Cancer Patient Populations.
Barnett S; Holden V; Campbell-Hewson Q; Veal GJ
Front Oncol; 2021; 11():815040. PubMed ID: 35071019
[TBL] [Abstract][Full Text] [Related]
33.
Huang J; Hao C; Li Z; Wang L; Jiang J; Tang W; Wang L; Zhang W; Hu J; Yang W
Front Pharmacol; 2020; 11():563321. PubMed ID: 33384597
[TBL] [Abstract][Full Text] [Related]
34. Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide Produces Comparable Outcomes to Four-Times-Daily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Hill BT; Rybicki L; Carlstrom KD; Jagadeesh D; Gerds A; Hamilton B; Liu H; Dean R; Sobecks R; Pohlman B; Andresen S; Kalaycio M; Bolwell BJ; Majhail NS
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1588-1595. PubMed ID: 27343718
[TBL] [Abstract][Full Text] [Related]
35. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.
Ulrickson M; Aldridge J; Kim HT; Hochberg EP; Hammerman P; Dube C; Attar E; Ballen KK; Dey BR; McAfee SL; Spitzer TR; Chen YB
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1447-54. PubMed ID: 19822305
[TBL] [Abstract][Full Text] [Related]
36. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
Hänel M; Kröger N; Sonnenberg S; Bornhäuser M; Krüger W; Kroschinsky F; Hänel A; Metzner B; Birkmann J; Schmid B; Hoffknecht MM; Fiedler F; Ehninger G; Zander AR
Ann Hematol; 2002 Feb; 81(2):96-102. PubMed ID: 11907790
[TBL] [Abstract][Full Text] [Related]
37. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
[TBL] [Abstract][Full Text] [Related]
38. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.
Gkotzamanidou M; Papadimitriou CA
Crit Rev Oncol Hematol; 2014 Feb; 89(2):248-61. PubMed ID: 24075060
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Hill BT; Rybicki LA; Urban TA; Lucena M; Jagadeesh D; Gerds AT; Dean RM; Sobecks RM; Pohlman B; Bolwell B; Kalaycio ME; Hamilton BK; Copelan EA; Majhail NS
Biol Blood Marrow Transplant; 2020 Feb; 26(2):262-271. PubMed ID: 31610237
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
